Original Source(s)
Related Content
FDA Approves First Oral PCSK9 Inhibitor
Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.
July 16, 2026
-
2 min
Oral Aleniglipron Reduced Weight at 36 Weeks
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
July 16, 2026
-
6 min